Health Discoveries in Mesothelioma

Drug for mesothelioma patients undergoes testing

October 19, 2010
The Southwest Oncology Group, an association of several cancer centers across the U.S., has begun testing a drug that it hopes will improve the effect of chemotherapy on mesothelioma patients.

The study, funded by the National Cancer Institute (NCI), is focused on the drug cediranib maleate - also known as AZD2171 or Recentin - used in conjunction with pemetrexed and cisplatin, two commonly-prescribed chemotherapy drugs.

According to the NCI clinical trial website, researchers are hoping the drug will not only stop the growth of mesothelioma cells, but also prevent the formation of blood vessels that feed them.

About 100 patients have been enrolled, but the study remains open to additional mesothelioma patients who haven't yet been treated with chemotherapy, radiation, surgery, hormone therapy or any other treatment.

The study sites for the Phase I/II trial are the M.D. Anderson Cancer Center in Houston, Texas, the Lucille Markey Cancer Center at the University of Kentucky in Lexington, Kentucky, and the Highlands Oncology Group in Bentonville, Arkansas.

The Cancer Institute within the North Shore-LIJ Health System has a multidisciplinary team of medical specialists who treat mesothelioma, both locally and systemically, with radiation, surgery and chemotherapy.
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Drug for mesothelioma patients undergoes testing: